Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis.
J Dermatolog Treat
; 34(1): 2220444, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-37272353
ABSTRACT
BACKGROUND:
Dupilumab facial redness (DFR) is a side effect of dupilumab treatment that has only been recently reported. We previously reported on two patients with DFR who were successfully treated with a topical formulation containing human adipose tissue-derived mesenchymal stem cell-derived exosomes (ASCEs).OBJECTIVES:
The study aimed to evaluate the efficacy and safety of ASCEs in DFR. PARTICIPANTS ANDMETHODS:
We performed 12-week prospective study at single center. Twenty adult atopic dermatitis patients diagnosed with DFR were enrolled. They were treated with a topical application of the exosome formulation every week for five consecutive weeks.RESULTS:
After exosome treatment, both the average investigator global assessment score and clinical erythema assessment scale scores decreased. 19 patients (95%) were satisfied with the treatment. Compared to baseline, erythema index at week 4 were decreased by 31, 27, 13, and 25 units on the forehead, chin, right and left cheek respectively. The analysis of stratum corneum samples revealed the expression of IL-1α and human thymic stromal lymphopoietin was suppressed after exosome treatment, whereas filaggrin and vascular endothelial growth factor expression increased.CONCLUSIONS:
This study suggests topical formulation containing ASCEs can alleviate DFR by downregulating local inflammation and restoring skin barrier function.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Dermatitis Atópica
/
Exosomas
Tipo de estudio:
Clinical_trials
/
Observational_studies
Límite:
Adult
/
Humans
Idioma:
En
Revista:
J Dermatolog Treat
Asunto de la revista:
DERMATOLOGIA
Año:
2023
Tipo del documento:
Article